SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)				3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 23, 2024	Sep. 17, 2024	Sep. 16, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jul. 31, 2023	May 10, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares authorized									120,000,000
Common stock, shares issued				100,000,000	100,000,000		100,000,000		100,000,000
Common stock, par value				$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized				20,000,000	20,000,000		20,000,000		20,000,000
Preferred stock par value				$ 0.001	$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued				12,846,785	12,846,785		10,562,640
Common stock, shares outstanding				12,846,785	12,846,785		10,562,640
Preferredstock, shares outstanding				0	0		0
Total gross proceeds					$ 5,524,000
Warrants exercise price				$ 4.29	$ 4.29
Conversion price per share					60.00%
Fair value of shares	$ 100,000
Annual cash compensation	50,000
Cash compensation	$ 10,000
Unamortized compensation					$ 169,000
Warrants outstanding, outstanding number of options, shares				278,188	278,188
Warrant expiration					1 year 7 days
Convertible note payable										$ 250,000
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	30,000
2023 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares							0
Common stock reserved for future issuance								1,650,000
Restricted units issued					80,000
Shares available for grant				1,570,000	1,570,000
Cedars Sinai Medical Center [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertion of accounts payable				$ 750,000
Convert shares				312,500
Fair value accounts payable				$ 1,250,000	$ 1,250,000
Financing cost				$ 500,000
Strategic Advisory Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares vested					0
Share-based compensation					$ 4,000
Strategic Advisory Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares	50,000
Directors Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of shares	$ 74,000
Directors Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares	10,000
Director Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares vested					0
Share-based compensation					$ 5,000
Director Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation					$ 1,000
IPO [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares			1,550,000
Share price			$ 4.00
Total gross proceeds			$ 6,200,000
Underwriting expense			$ 5,524,000
Additional shares issued			232,500
IPO [Member] | Underwrinting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares		54,250
IPO price percentage		120.00%
Warrants exercise price		$ 4.80
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferredstock, shares outstanding				0	0		0
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares				1,550,000	1,550,000
Additional shares issued				1,664	1,664
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercise price		$ 4.80								$ 4.17
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross					128,188
Purchase of warrants		54,250		278,188	278,188		150,000			150,000
Warrants exercise price percentage		120.00%
Warrant shares outstanding, intrinsic value				$ 0	$ 0
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price		$ 2.46
Warrants exercise price		$ 2.40		$ 2.40	$ 2.40
Warrants outstanding, outstanding number of options, shares		19,688		19.688	19.688
Expected term		2 years 6 months
Volatility		100.00%
Dividend rate		0.00%
Risk free interest rate		3.49%
Fair value of Warrant				$ 29,000	$ 29,000
Warrant expiration		5 years			5 years